Placing New MPN Therapies into Context Through Illustrated Case Discussions

thehealthco

Advances in the understanding of the pathogenesis of the myeloproliferative neoplasms (MPNs), polycythemia vera (PV) and primary myelofibrosis (MF), have led to improved treatment interventions. Approximately 95% of patients with PV and 50% of patients with MF have mutations in Janus kinase 2 (JAK2), which is essential for the normal development of granulocytes, erythrocytes, and platelets. Other less common shared mutations include CALR (calreticulin mutation) and MPL (myeloproliferative leukemia virus oncogene). Identification of mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies is paramount to improving outcomes for patients.

June 5, 2022 | Hilton Chicago, IL 

Read More

Next Post

How healthcare orgs can protect their supply chain from cyber risks

The Cloud Security Alliance this past week released a report outlining the cyber risks faced by healthcare delivery organizations when it comes to supply chain management. Experts from CSA explained that healthcare organizations face two main concerns: Risk management involving the cyber supply chain, which includes IT networks, hardware and […]
thehealthco